Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/CDT Equity Inc./ 10-Q

Quarterly Report · 10-Q

CDT Equity Inc.

CDTNASDAQEQUITYCurrent

Quarterly Report

Filed Nov 14, 2024Accepted Nov 14, 2024, 5:27 PM ESTCIK 1896212Accession 0001493152-24-046088
View company →Permanent SEC source ↗
Share

Company context

CDT Equity is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments.

Current securities

CDTNASDAQ · EQUITY · CurrentCDTTWNASDAQ · WARRANT · Current
Historical securities (3)
MURFNASDAQ · EQUITY · Historical · closed Sep 22, 2023MURFUNASDAQ · UNIT · Historical · closed Sep 22, 2023MURFWNASDAQ · WARRANT · Historical · closed Sep 22, 2023

Recent company filings

  1. 424B3 filingNov 4, 2026
  2. Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearNov 4, 2026
  3. 424B3 filingNov 3, 2026
  4. DEF 14A filingOct 27, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 27, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.